Header Logo

Search Results (270)

MatchTypeWhy
Usmani, SaadPerson Why?
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.Academic Article Why?
Multiple myeloma.Academic Article Why?
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.Academic Article Why?
Adenovirus vector-based purging of multiple myeloma cells.Academic Article Why?
An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.Academic Article Why?
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.Academic Article Why?
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.Academic Article Why?
Bone Health and Survival in Women With Multiple Myeloma.Academic Article Why?
Bruceantin inhibits multiple myeloma cancer stem cell proliferation.Academic Article Why?
CAR T-cell therapy for multiple myeloma: state of the art and prospects.Academic Article Why?
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.Academic Article Why?
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.Academic Article Why?
Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma.Academic Article Why?
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.Academic Article Why?
Per Page    Page  of 18last Nextnext
Prev
Search Criteria
  • Multiple Myeloma
Filter by Type
_
Click "Why?" to see why an item matched the search.